The 36-month beta value for RLYB is also noteworthy at -2.12. There are mixed opinions on the stock, with 7 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The average price estimated by analysts for RLYB is $17.00, which is $14.55 above than the current price. The public float for RLYB is 16.88M, and at present, short sellers hold a 12.56% of that float. The average trading volume of RLYB on November 21, 2023 was 55.18K shares.

Elon Musk just Triggered a BOOM in These Stocks

Something strange is happening in the stock market…. This select group of stocks are going absolutely bananas. And it's all because of Elon Musk. Get your copy of "Top 5 Tech Stocks to Buy in 2024"

Click Here to Download the FREE Report.


RLYB) stock’s latest price update

The stock of Rallybio Corp (NASDAQ: RLYB) has increased by 23.12 when compared to last closing price of 1.99.Despite this, the company has seen a loss of -3.54% in its stock price over the last five trading days. Seeking Alpha reported 2023-09-15 that Rallybio has proof of concept data from two more assets, RLYB211 and RLYB116, in addition to their lead asset RLYB212. RLYB212 demonstrated rapid and complete elimination of transfused platelets in patients, while RLYB116 showed a reduction in Free C5 greater than 99%. The company has a cash balance of $138mn and a cash runway of approximately 6 quarters.

RLYB’s Market Performance

Rallybio Corp (RLYB) has experienced a -3.54% fall in stock performance for the past week, with a -27.51% drop in the past month, and a -54.63% drop in the past quarter. The volatility ratio for the week is 14.37%, and the volatility levels for the past 30 days are at 13.24% for RLYB. The simple moving average for the past 20 days is -26.17% for RLYB’s stock, with a -55.25% simple moving average for the past 200 days.

Analysts’ Opinion of RLYB

Many brokerage firms have already submitted their reports for RLYB stocks, with H.C. Wainwright repeating the rating for RLYB by listing it as a “Buy.” The predicted price for RLYB in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on April 17, 2023 of the current year 2023.

RLYB Trading at -35.74% from the 50-Day Moving Average

After a stumble in the market that brought RLYB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.19% of loss for the given period.

Volatility was left at 13.24%, however, over the last 30 days, the volatility rate increased by 14.37%, as shares sank -29.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -54.21% lower at present.

During the last 5 trading sessions, RLYB fell by -3.54%, which changed the moving average for the period of 200-days by -62.02% in comparison to the 20-day moving average, which settled at $3.2700. In addition, Rallybio Corp saw -62.71% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at RLYB starting from Lieber Jonathan I, who purchase 5,000 shares at the price of $5.21 back on Mar 14. After this action, Lieber Jonathan I now owns 5,000 shares of Rallybio Corp, valued at $26,050 using the latest closing price.

PARMAR KUSH, the Director of Rallybio Corp, sale 100,000 shares at $8.20 during a trade that took place back on Mar 07, which means that PARMAR KUSH is holding 2,378,969 shares at $820,000 based on the most recent closing price.

Stock Fundamentals for RLYB

The total capital return value is set at -39.30, while invested capital returns managed to touch -38.61. Equity return is now at value -55.20, with -50.95 for asset returns.

Based on Rallybio Corp (RLYB), the company’s capital structure generated 0.33 points at debt to equity in total, while total debt to capital is 0.33. Total debt to assets is 0.31, with long-term debt to equity ratio resting at 0.22. Finally, the long-term debt to capital ratio is 0.22.

The liquidity ratio also appears to be rather interesting for investors as it stands at 16.71.


In summary, Rallybio Corp (RLYB) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.